NMO - MOG ANTIBODIES in Kolkata

NMO - MOG Antibodies Test: Price, Purpose, Range & Reports
 

The NMO - MOG Antibodies Test is a highly specialised blood test used to diagnose and differentiate two major autoimmune inflammatory disorders of the central nervous system (CNS): Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD). These conditions can mimic Multiple Sclerosis (MS) but require distinct and urgent treatment approaches. This panel specifically detects two critical autoantibodies: Aquaporin-4 (AQP4) IgG, the marker for NMOSD, and Myelin Oligodendrocyte Glycoprotein (MOG) IgG, the marker for MOGAD. Early and accurate diagnosis using this test is vital for preventing permanent neurological damage. 

What is the NMO - MOG Antibodies Test?

The NMO-MOG antibodies test is a blood test that helps doctors diagnose certain autoimmune conditions that affect the central nervous system. It checks for two specific antibodies: Aquaporin-4 Immunoglobulin G (AQP4-IgG), which is linked to Neuromyelitis Optica Spectrum Disorder (NMOSD), and Myelin Oligodendrocyte Glycoprotein Immunoglobulin G (MOG-IgG), which is linked to MOG Antibody Disease (MOGAD).
These conditions can cause symptoms like vision loss, muscle weakness, and problems with coordination. Because they often look similar to multiple sclerosis, this test helps doctors make a clearer diagnosis and choose the right treatment. Getting the correct result early can lead to faster care and better long-term outcomes.

What is the NMO - MOG Antibodies Test Price?

The price of the NMO - MOG Antibodies Test is typically higher than general blood panels due to the complexity and specialised nature of the analysis. The testing requires advanced techniques, such as Cell-Based Assays (CBA), which are the gold standard for reliably detecting these specific autoantibodies. Several factors influence the final cost of the test:

•    Technology Used: Accurate detection often requires specialised Cell-Based Assays (CBA), which use live or fixed cells expressing the target antigens (AQP4 or MOG). These methods are superior to older, less sensitive techniques.
•    Location and Logistics: Since this test is highly specialised, samples often need to be shipped to specialised neuroimmunology reference laboratories, which adds to the logistical cost.
•    Lab Specialisation: The testing is usually only performed by high-complexity, accredited laboratories with expertise in neuroimmunology.
•    Panels vs. Individual Tests: The cost may reflect whether AQP4 and MOG are ordered as a combined panel or as separate assays.
If you're looking for the most accurate and affordable NMO - MOG Antibodies Test price near me, the best way to check is through the Apollo 24|7 website or app. Prices are updated regularly based on your location, and you’ll be able to view the latest rates along with any available discounts or offers.

What is the Purpose of the NMO - MOG Antibodies Test?

The primary purpose of the NMO - MOG Antibodies Test is definitive diagnosis and differential diagnosis within the spectrum of inflammatory CNS diseases:

•    Confirming NMOSD: A positive AQP4 IgG result confirms the diagnosis of NMOSD, guiding the clinician to initiate treatments specifically designed to target the AQP4-mediated inflammation.
•    Confirming MOGAD: A positive MOG IgG result confirms MOGAD, leading to MOGAD-specific treatment protocols, which often differ from those for NMOSD and MS.
•    Excluding MS: A positive result for either AQP4 or MOG effectively rules out typical Multiple Sclerosis, preventing the use of ineffective or potentially harmful MS medications.
•    Risk Stratification: The test can help predict the likelihood of recurrence and disease severity, influencing the choice of long-term immunosuppressive therapy.

Who Should Get an NMO - MOG Antibodies Test Done?

This specialised test is typically ordered by neurologists or neuroimmunologists when a patient presents with symptoms highly suggestive of NMOSD or MOGAD. This test is advised for individuals who have experienced:

•    Severe or Recurrent Optic Neuritis: Especially if the optic nerve damage is bilateral (in both eyes) or causes severe vision loss.
•    Longitudinally Extensive Transverse Myelitis (LETM): Spinal cord inflammation that spans three or more vertebral segments, a hallmark feature of NMOSD.
•    Acute Disseminated Encephalomyelitis (ADEM): Particularly in children or young adults.
•    Unusual Clinical Presentations: Patients whose symptoms are atypical for MS or whose MRI findings do not align with MS criteria.

Components of the NMO - MOG Antibodies Test

The NMO - MOG Antibodies Test measures the presence of two distinct autoantibodies in the blood (serum):

•    Aquaporin-4 (AQP4) IgG: These antibodies target a water channel protein found primarily on astrocytes in the CNS. A positive result is highly specific for Neuromyelitis Optica Spectrum Disorder (NMOSD), formerly known as Devic's Disease. NMOSD typically causes severe, recurrent attacks of optic neuritis (inflammation of the optic nerve) and/or transverse myelitis (inflammation of the spinal cord).
o    Reported as Positive, Negative, or a specific Titer (e.g., 1:100).
•    Myelin Oligodendrocyte Glycoprotein (MOG) IgG: These antibodies target MOG, a protein found on the surface of myelin-producing cells (oligodendrocytes). A positive result confirms Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD). MOGAD can also cause optic neuritis and transverse myelitis, but often presents with unique symptoms like Acute Disseminated Encephalomyelitis (ADEM).
o    Reported as Positive, Negative, or a specific Titer (e.g., 1:256)

Understanding an NMO - MOG Antibodies Test Report

The NMO-MOG antibodies test helps diagnose two distinct neurological conditions: neuromyelitis optica spectrum disorder (NMOSD) and MOG-associated disease (MOGAD). These disorders affect the central nervous system and often present with symptoms similar to multiple sclerosis, making an accurate diagnosis essential for proper treatment.
Here is a simplified guide to interpreting the test results:
 

Important Note: 

•    A positive antibody result is highly suggestive but not definitive on its own.
•    Diagnosis requires correlation with clinical symptoms (such as optic neuritis, transverse myelitis, or brainstem syndromes) and MRI findings.
•    Antibody levels may be affected by recent immunosuppressive treatment, which can lead to false-negative results.
If your test is positive for either antibody, your doctor will likely recommend further imaging and clinical evaluation to confirm the diagnosis and begin appropriate treatment. If the test is negative but symptoms persist, additional investigations may be needed to explore other neurological conditions.
Always discuss your test results with a neurologist or neuroimmunologist to ensure accurate interpretation and personalised care.

Preparation and Procedure for NMO - MOG Antibodies Test

The NMO-MOG antibodies test is a simple and important blood test used to detect autoimmune markers associated with neuromyelitis optica spectrum disorder (NMOSD) and MOG-associated disease. Here's what you need to know before and during the test:

1. How is the Test Done? 

A healthcare professional will draw a blood sample from a vein in your arm using a standard venipuncture technique. The blood is collected into a plain tube, allowed to clot, and the serum is separated. This serum is then sent to a specialised laboratory for analysis using a method called cell-based assay (CBA), which is designed to detect NMO and MOG antibodies with high sensitivity.

2. Is Fasting Required? 

No fasting is needed for this test. You can eat and drink normally before your appointment.

3. What Time of Day Should I Take the Test? 

There’s no specific time requirement. These antibodies are stable throughout the day, so the timing of your blood draw will not affect the results.

4. Should I Tell My Doctor About My Medications? 

Yes, it’s very important to inform your doctor about any medications you’re taking, especially immunosuppressive drugs or corticosteroids. These treatments can reduce antibody levels and may lead to a false negative result if the test is done too soon after starting or receiving acute therapy.

5. How Often Do I Need This Test? 

In most cases, the test is done once to confirm a diagnosis. However, your doctor may recommend repeat testing if your initial result was unclear, if symptoms persist, or if you’ve recently started or changed immunosuppressive treatment. Follow-up testing may also be used to monitor disease progression or treatment response.

Booking NMO - MOG Antibodies Test Online & Checking Reports

Apollo 24|7 offers a seamless process for scheduling this important test and accessing your results.

A. How to Schedule the Test on Apollo 24|7

•    Visit the Apollo 24|7 platform and search for NMO - MOG Antibodies Test.
•    Review the latest NMO - MOG Antibodies Test price for your location and click 'Book Now'.
•    Select a convenient date and time for the sample collection at the designated facility/lab centre.
•    Complete the secure online payment to confirm your booking.

B. How to Access Your Test Results Online

•    Log in to your Apollo 24|7 account via the website or mobile app.
•    Navigate to the 'Health Records' or 'My Reports' section.
•    Click on the completed NMO - MOG Antibodies Test report.
•    You can view and download the detailed report in PDF format, which must be shared with your neurologist or neuroimmunologist for critical interpretation and management decisions.

Conclusion

The NMO - MOG Antibodies Test is a vital tool in diagnosing autoimmune disorders of the central nervous system (CNS). It helps distinguish between Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD), which often present with similar symptoms but require different treatments. By accurately identifying Aquaporin-4 Immunoglobulin G (AQP4-IgG) or Myelin Oligodendrocyte Glycoprotein Immunoglobulin G (MOG-IgG) antibodies, this test ensures patients receive the correct, potentially life-saving immunotherapy as early as possible.